Use of lenalidomide in the management of relapsed or refractory multiple myeloma: Expert recommendations in Korea

The Korean Multiple Myeloma Working Party

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Multiple myeloma (MM) is the third most common hematologic malignancy in Korea. Historically, the incidence of MM in Korea has been lower than that in Western populations, although there is growing evidence that the incidence of MM in Asian populations, including Korea, is increasing rapidly. Despite advances in the management of MM, patients will ultimately relapse or become refractory to their current treatment, and alternative therapeutic options are required in the relapsed/refractory setting. In Korea, although lenalidomide/dexamethasone is indicated for the treatment of relapsed or refractory MM (RRMM) in patients who have received at least one prior therapy, lenalidomide is reimbursable specifically only in patients with RRMM who have failed bortezomib- based treatment. Based on evidence from pivotal multinational clinical trials as well as recent studies in Asia, including Korea, lenalidomide/dexamethasone is an effective treatment option for patients with RRMM, regardless of age or disease status. Adverse events associated with lenalidomide/dexamethasone, including hematologic toxicity, venous thromboembolism, fatigue, rash, infection, and muscle cramps, are largely predictable and preventable/manageable with appropriate patient monitoring and/or the use of standard supportive medication and dose adjustment/interruption. Lenalidomide/dexamethasone provides an optimal response when used at first relapse, and treatment should be continued long term until disease progression. With appropriate modification of the lenalidomide starting dose, lenalidomide/dexamethasone is effective in patients with renal impairment and/or cytopenia. This review presents updated evidence from the published clinical literature and provides recommendations from an expert panel of Korean physicians regarding the use of lenalidomide/dexamethasone in patients with RRMM.

Original languageEnglish
Pages (from-to)7-18
Number of pages12
JournalBlood Research
Volume50
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Korea
Multiple Myeloma
Dexamethasone
Therapeutics
Muscle Cramp
Recurrence
lenalidomide
Incidence
Venous Thromboembolism
Physiologic Monitoring
Hematologic Neoplasms
Exanthema
Population
Fatigue
Disease Progression
Clinical Trials
Physicians
Kidney
Infection

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

@article{29bba2aeace746b7a02e22de3967570a,
title = "Use of lenalidomide in the management of relapsed or refractory multiple myeloma: Expert recommendations in Korea",
abstract = "Multiple myeloma (MM) is the third most common hematologic malignancy in Korea. Historically, the incidence of MM in Korea has been lower than that in Western populations, although there is growing evidence that the incidence of MM in Asian populations, including Korea, is increasing rapidly. Despite advances in the management of MM, patients will ultimately relapse or become refractory to their current treatment, and alternative therapeutic options are required in the relapsed/refractory setting. In Korea, although lenalidomide/dexamethasone is indicated for the treatment of relapsed or refractory MM (RRMM) in patients who have received at least one prior therapy, lenalidomide is reimbursable specifically only in patients with RRMM who have failed bortezomib- based treatment. Based on evidence from pivotal multinational clinical trials as well as recent studies in Asia, including Korea, lenalidomide/dexamethasone is an effective treatment option for patients with RRMM, regardless of age or disease status. Adverse events associated with lenalidomide/dexamethasone, including hematologic toxicity, venous thromboembolism, fatigue, rash, infection, and muscle cramps, are largely predictable and preventable/manageable with appropriate patient monitoring and/or the use of standard supportive medication and dose adjustment/interruption. Lenalidomide/dexamethasone provides an optimal response when used at first relapse, and treatment should be continued long term until disease progression. With appropriate modification of the lenalidomide starting dose, lenalidomide/dexamethasone is effective in patients with renal impairment and/or cytopenia. This review presents updated evidence from the published clinical literature and provides recommendations from an expert panel of Korean physicians regarding the use of lenalidomide/dexamethasone in patients with RRMM.",
author = "{The Korean Multiple Myeloma Working Party} and Kim, {Hyo Jung} and Yoon, {Sung Soo} and Eom, {Hyeon Seok} and Kihyun Kim and Kim, {Jin Seok} and Lee, {Je Jung} and Bang, {Soo Mee} and Min, {Chang Ki} and Park, {Joon Seong} and Lee, {Jae Hoon}",
year = "2015",
month = "1",
day = "1",
doi = "10.5045/br.2015.50.1.7",
language = "English",
volume = "50",
pages = "7--18",
journal = "Blood Research",
issn = "2287-979X",
publisher = "Korean Society of Hematology",
number = "1",

}

Use of lenalidomide in the management of relapsed or refractory multiple myeloma : Expert recommendations in Korea. / The Korean Multiple Myeloma Working Party.

In: Blood Research, Vol. 50, No. 1, 01.01.2015, p. 7-18.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Use of lenalidomide in the management of relapsed or refractory multiple myeloma

T2 - Expert recommendations in Korea

AU - The Korean Multiple Myeloma Working Party

AU - Kim, Hyo Jung

AU - Yoon, Sung Soo

AU - Eom, Hyeon Seok

AU - Kim, Kihyun

AU - Kim, Jin Seok

AU - Lee, Je Jung

AU - Bang, Soo Mee

AU - Min, Chang Ki

AU - Park, Joon Seong

AU - Lee, Jae Hoon

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Multiple myeloma (MM) is the third most common hematologic malignancy in Korea. Historically, the incidence of MM in Korea has been lower than that in Western populations, although there is growing evidence that the incidence of MM in Asian populations, including Korea, is increasing rapidly. Despite advances in the management of MM, patients will ultimately relapse or become refractory to their current treatment, and alternative therapeutic options are required in the relapsed/refractory setting. In Korea, although lenalidomide/dexamethasone is indicated for the treatment of relapsed or refractory MM (RRMM) in patients who have received at least one prior therapy, lenalidomide is reimbursable specifically only in patients with RRMM who have failed bortezomib- based treatment. Based on evidence from pivotal multinational clinical trials as well as recent studies in Asia, including Korea, lenalidomide/dexamethasone is an effective treatment option for patients with RRMM, regardless of age or disease status. Adverse events associated with lenalidomide/dexamethasone, including hematologic toxicity, venous thromboembolism, fatigue, rash, infection, and muscle cramps, are largely predictable and preventable/manageable with appropriate patient monitoring and/or the use of standard supportive medication and dose adjustment/interruption. Lenalidomide/dexamethasone provides an optimal response when used at first relapse, and treatment should be continued long term until disease progression. With appropriate modification of the lenalidomide starting dose, lenalidomide/dexamethasone is effective in patients with renal impairment and/or cytopenia. This review presents updated evidence from the published clinical literature and provides recommendations from an expert panel of Korean physicians regarding the use of lenalidomide/dexamethasone in patients with RRMM.

AB - Multiple myeloma (MM) is the third most common hematologic malignancy in Korea. Historically, the incidence of MM in Korea has been lower than that in Western populations, although there is growing evidence that the incidence of MM in Asian populations, including Korea, is increasing rapidly. Despite advances in the management of MM, patients will ultimately relapse or become refractory to their current treatment, and alternative therapeutic options are required in the relapsed/refractory setting. In Korea, although lenalidomide/dexamethasone is indicated for the treatment of relapsed or refractory MM (RRMM) in patients who have received at least one prior therapy, lenalidomide is reimbursable specifically only in patients with RRMM who have failed bortezomib- based treatment. Based on evidence from pivotal multinational clinical trials as well as recent studies in Asia, including Korea, lenalidomide/dexamethasone is an effective treatment option for patients with RRMM, regardless of age or disease status. Adverse events associated with lenalidomide/dexamethasone, including hematologic toxicity, venous thromboembolism, fatigue, rash, infection, and muscle cramps, are largely predictable and preventable/manageable with appropriate patient monitoring and/or the use of standard supportive medication and dose adjustment/interruption. Lenalidomide/dexamethasone provides an optimal response when used at first relapse, and treatment should be continued long term until disease progression. With appropriate modification of the lenalidomide starting dose, lenalidomide/dexamethasone is effective in patients with renal impairment and/or cytopenia. This review presents updated evidence from the published clinical literature and provides recommendations from an expert panel of Korean physicians regarding the use of lenalidomide/dexamethasone in patients with RRMM.

UR - http://www.scopus.com/inward/record.url?scp=84926369178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926369178&partnerID=8YFLogxK

U2 - 10.5045/br.2015.50.1.7

DO - 10.5045/br.2015.50.1.7

M3 - Review article

AN - SCOPUS:84926369178

VL - 50

SP - 7

EP - 18

JO - Blood Research

JF - Blood Research

SN - 2287-979X

IS - 1

ER -